glutamine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1311 56-85-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • L-Glutamine
  • glutamine
  • glutamic acid amide
  • L-(+)-Glutamine
  • L-2-Aminoglutaramidic acid
  • levoglutamide
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.
  • Molecular weight: 146.15
  • Formula: C5H10N2O3
  • CLOGP: -3.37
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 106.41
  • ALOGS: -0.17
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 10, 2004 FDA EMMAUS MEDCL

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC A16AA03 ALIMENTARY TRACT AND METABOLISM
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
Amino acids and derivatives
FDA EPC N0000175780 Amino Acid
FDA CS M0000922 Amino Acids

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Short bowel syndrome indication 26629001 DOID:10605
Hb SS disease symptomatic treatment 127040003 DOID:10923

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.17 acidic
pKa2 12.12 acidic
pKa3 9.22 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
5GM/PACKET ENDARI EMMAUS MEDCL N208587 July 7, 2017 RX FOR SOLUTION ORAL July 7, 2020 TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS FIVE YEARS OF AGE AND OLDER
5GM/PACKET ENDARI EMMAUS MEDCL N208587 July 7, 2017 RX FOR SOLUTION ORAL July 7, 2024 TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.

Bioactivity Summary:

None

External reference:

IDSource
D005973 MESH_DESCRIPTOR_UI
4027901 VUID
N0000177918 NUI
C0017797 UMLSCUI
0RH81L854J UNII
1413 INN_ID
412421007 SNOMEDCT_US
4885 RXNORM
25761002 SNOMEDCT_US
4025874 VANDF
12067 MMSL
d07315 MMSL
4027901 VANDF
158601 MMSL
158599 MMSL
000928 NDDF
5961 PUBCHEM_CID
CHEBI:28300 CHEBI
CHEMBL930 ChEMBL_ID
DB00130 DRUGBANK_ID
723 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Endari HUMAN PRESCRIPTION DRUG LABEL 1 42457-420 POWDER, FOR SOLUTION 5 g ORAL NDA 16 sections